Literature DB >> 33470407

The regulatory effect of 6-TG on lncRNA-miRNA-mRNA ceRNA network in triple-negative breast cancer cell line.

Daoyu Zhang1, Xinglan An1, Hao Yu2, Ziyi Li1.   

Abstract

Breast cancer is one of the most prevalent and recurring cancer types that leads to deaths in women. Triple-negative breast cancer (TNBC) is difficult to treat due to the lack of therapeutic targets. Many studies have focused on identifying drugs for use as alternative treatments for breast cancer. Thioguanine (6-TG) exerts antitumor effects in cancer. Increasing evidence has demonstrated that competitive endogenous ribonucleic acids (ceRNAs) are involved in cancer processes. However, the mechanism by which 6-TG regulates lncRNA-miRNA-mRNAs has not been elucidated. We evaluated the antitumor effect of 6-TG in MDA-MB-231 cells and comprehensively analyzed the RNA-Seq data of MDA-MB-231 cells treated with 6-TG. Our results showed that most tumor pathways were blocked by 6-TG. The hub genes were FN1, FLNA, FLNB, VCL, GSN, MYH10, ACTN4, KDR and EREG, and they were all down-regulated after 6-TG treatment. The coexpression network consisted of 18 microRNAs (miRNAs), 9 long noncoding RNAs (lncRNAs) and 20 mRNAs. Hsa-mir-16-5p and Hsa-mir-335-5p targeted the greatest number of mRNAs in the network. These molecules could bind to PAX8-AS1 and eliminate the inhibition of target mRNA expression. We showed that PAX8-AS1 is the main lncRNA affected by 6-TG and that PAX8-AS1 regulates the hub genes in tumor pathways by competitively binding with miR-16-5p and miR-335-5p.
© 2021 The Author(s).

Entities:  

Keywords:  Thioguanine (6-TG); Triple-negative breast cancer (TNBC); ceRNA

Mesh:

Substances:

Year:  2021        PMID: 33470407      PMCID: PMC7859320          DOI: 10.1042/BSR20203890

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  30 in total

Review 1.  ceRNA in cancer: possible functions and clinical implications.

Authors:  Xiaolong Qi; Da-Hong Zhang; Nan Wu; Jun-Hua Xiao; Xiang Wang; Wang Ma
Journal:  J Med Genet       Date:  2015-09-10       Impact factor: 6.318

Review 2.  6-thioguanine: a drug with unrealized potential for cancer therapy.

Authors:  Pashna N Munshi; Martin Lubin; Joseph R Bertino
Journal:  Oncologist       Date:  2014-06-13

3.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

4.  DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.

Authors:  Tao Yan; Suzanne E Berry; Anand B Desai; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

Review 5.  The multilayered complexity of ceRNA crosstalk and competition.

Authors:  Yvonne Tay; John Rinn; Pier Paolo Pandolfi
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

Review 6.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

Review 7.  An overview of triple-negative breast cancer.

Authors:  Pankaj Kumar; Rupali Aggarwal
Journal:  Arch Gynecol Obstet       Date:  2015-09-04       Impact factor: 2.344

8.  Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis.

Authors:  Xue Zhu; Ke Wang; Kai Zhang; Ting Zhang; Yongxiang Yin; Fei Xu
Journal:  Int J Mol Sci       Date:  2016-11-22       Impact factor: 5.923

9.  Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts.

Authors:  Yasuhiro Suzuki; Shuji Kitahara; Takuya Suematsu; Masanobu Oshima; Yasufumi Sato
Journal:  Cancer Sci       Date:  2017-10-21       Impact factor: 6.716

10.  Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.

Authors:  Bin Bao; Cristina Mitrea; Priyanga Wijesinghe; Luca Marchetti; Emily Girsch; Rebecca L Farr; Julie L Boerner; Ramzi Mohammad; Greg Dyson; Stanley R Terlecky; Aliccia Bollig-Fischer
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

View more
  3 in total

1.  Overexpression of PAX8-AS1 Inhibits Malignant Phenotypes of Papillary Thyroid Carcinoma Cells via miR-96-5p/PKN2 Axis.

Authors:  Ping Zhou; Tongdao Xu; Hao Hu; Fei Hua
Journal:  Int J Endocrinol       Date:  2021-10-26       Impact factor: 3.257

2.  SLC7A11, a Potential Therapeutic Target Through Induced Ferroptosis in Colon Adenocarcinoma.

Authors:  Xin Cheng; Yadong Wang; Liangchao Liu; Chenggang Lv; Can Liu; Jingyun Xu
Journal:  Front Mol Biosci       Date:  2022-04-20

3.  Bioinformatics analysis of long non-coding RNA-associated competing endogenous RNA network in schizophrenia.

Authors:  Hani Sabaie; Madiheh Mazaheri Moghaddam; Marziyeh Mazaheri Moghaddam; Noora Karim Ahangar; Mohammad Reza Asadi; Bashdar Mahmud Hussen; Mohammad Taheri; Maryam Rezazadeh
Journal:  Sci Rep       Date:  2021-12-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.